Physician profile
Terri Washington
NPI 1114120722
$47,850.24
in general payments reported to CMS, 2019-2025
30 companies · $2,907 in 2025
The $2,907 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $2,877 · 2021: $666 · 2022: $3,460 · 2023: $11K · 2024: $2,111 · 2025: $2,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $2,601 · Travel and Lodging: $1,394 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,352.50 |
| Food and Beverage | $2,600.81 |
| Travel and Lodging | $1,393.92 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $22,171.38 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $20,976.18 | 2019-2020 | |
| Corcept Therapeutics | $1,848.99 | 2022-2025 | Korlym |
| Insulet Corporation | $517.49 | 2019-2025 | Omnipod |
| Amgen INC. | $304.39 | 2021-2025 | Tepezza |
| Dexcom, INC. | $248.73 | 2019-2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $221.47 | 2023 | Tepezza |
| Tandem Diabetes Care, INC. | $199.79 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $182.35 | 2020-2023 | Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $171.02 | 2020-2024 | |
| Abbott Laboratories | $161.87 | 2020-2024 | Freestyle Libre 3, Proclaim, Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.66 | 2019-2025 | Jardiance |
| Recordati_rare_diseases_inc. | $100.84 | 2025 | Isturisa |
| Astrazeneca Pharmaceuticals LP | $95.34 | 2021-2022 | |
| Abbvie INC. | $95.29 | 2022-2023 | Synthroid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $90.26 | 2023 | Veozah |
| Ibsa Pharma INC. | $35.70 | 2019-2025 | Tirosint, Flector, Licart |
| Xeris Pharmaceuticals, INC. | $34.23 | 2022-2023 | Recorlev |
| Currax Pharmaceuticals LLC | $31.07 | 2023-2025 | Contrave, Nexletol, Nexlizet |
| Ascendis Pharma Endocrinology INC | $27.33 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $25.90 | 2025 | Twiist |
| Amneal Pharmaceuticals LLC | $23.87 | 2021 | |
| Theracosbio, LLC | $20.12 | 2024 | Brenzavvy |
| Mannkind Corporation | $20.00 | 2023 | Afrezza |
| Antares Pharma, INC. | $16.92 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $15.83 | 2025 | Imcivree |
| Beta Bionics, INC. | $15.58 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $15.27 | 2021 | |
| Upsher-Smith Laboratories LLC | $11.37 | 2019 | |
| Senseonics, Incorporated | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Washington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.